%PDF-1.7
%
1 0 obj
<>stream
VoR
10.1111/1759-7714.14256
10.1111/1759-7714.14256
10.1111/(ISSN)1759-7714
3
Host immune‐inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD‐L1 ≥50% metastatic non‐small cell lung cancer and poor performance status receiving first‐line immunotherapy
Acrobat Distiller 11.0 (Windows); modified using iText 4.2.0 by 1T3XT2022-01-09T05:53:20-08:00
endstream
endobj
4 0 obj
<>stream
h[ْFy'B"X_Z*ɶҪr8&~@*AI˟3172ܛ .Ur#fn.L& nyxݙeb&G$דwfWta31UWL\.K'|Xb>df ]Sb
qʕ6gK\>Y«,AEۭWߚ4/#0[*#d:;_,zU`0)$uBf &ꉃF:968ZhbZ^hsev7rbk1QyeAU4 _Sm3]/Wg5\(;\p4Ƞ.`̼xȠ|@<}+D~j"_9s`|s&C!ạsY96;mGĐ`[KbZpގ>'"EPɁ_F)7Ppb74ÝM~ySpPOWˀwZyi7*W#cK26v{??o#an0-f%Mw6`qGmdaLgFoN5)WmIacIf;jR۴ѳO!C<"$u~7]#7ZBt⪆hGoYIWe~ͺ"B1&Ӓa5Dfc`-pnнtaW鸔PT@QS"4Q܃v qb~S/蚍66zSSkBO4H&Yg2J.mO?/uQɀGd졈n2A)sz~CUBBE*?,k͵VX+&Og9M#FɈcjk'}^j#R[}11y+ϊ1efЈkcF|Y4vֵ7{5#Ucl:h>N=m7SDž
DvlWnt"| 9p*
eF|!Y9CWͲ,9gvyY條lQ>FKn7\x}:cw
KZy#Ͷ4hWBg"d(ՅlfW!d%=ͣvpUUMݪޒ"I~3m xwlr>iH9]8.!hBiM|ͱel%VNu'aCpGAec+d3uUeqaDn vÁD;,"WsG0'(es~֏%r]JA-2K߰4B?'Z"W#Yf{@=$
]՜ݢŹ2ɒUf"XmC-flaj)b%8j&iPp)aTYM=Mo+v@`B[ӨA3S-YX4,~rܘ̳?6|KmL즩a"L6ѵO-gBr44vZpCy2oDNc1}ύ'5ȫ,Ch;\UGF8B>
cf;L鱘rE,aJFwiibReܵ4#lTlfMn<ڌ?]$ڄ+$vzNE4ќ 7>=aUFJh\JLlJ]M4Mzh;6a$7y@Okd/h7m"b[W9jrBwe;`